Posted by admin on Aug 13th, 2022
Sanara MedTech (NASDAQ:SMTI – Get Rating) is set to post its quarterly earnings results after the market closes on Monday, August 15th. Individual interested in registering for the company’s earnings conference call can do so using this link.
Sanara MedTech (NASDAQ:SMTI – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.41) earnings per share (EPS) for the quarter. The firm had revenue of $7.81 million during the quarter. Sanara MedTech had a negative net margin of 36.63% and a negative return on equity of 31.14%. On average, analysts expect Sanara MedTech to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
NASDAQ:SMTI opened at $28.22 on Friday. The stock has a fifty day moving average price of $23.41 and a 200-day moving average price of $24.40. The company has a market cap of $225.14 million, a price-to-earnings ratio of -20.87 and a beta of 2.19. Sanara MedTech has a fifty-two week low of $17.41 and a fifty-two week high of $38.99.
Separately, Cantor Fitzgerald upped their target price on Sanara MedTech from $40.00 to $50.00 in a report on Friday, July 15th.
An institutional investor recently raised its position in Sanara MedTech stock. State Street Corp boosted its position in Sanara MedTech Inc. (NASDAQ:SMTI – Get Rating) by 8.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,013 shares of the company’s stock after acquiring an additional 613 shares during the period. State Street Corp owned 0.10% of Sanara MedTech worth $222,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 4.35% of the company’s stock.
Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
Solo Brands (NYSE:DTC) Shares Down 7% on Analyst Downgrade
Medicenna Therapeutics (MDNA) to Announce Quarterly Earnings on Monday